Guard Therapeutics today announced that an independent Data Safety Monitoring Committee (DSMC) has completed the second and final planned review of safety data from the ongoing Phase 2b clinical trial ...

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

Artedrone is trying to raise a €20 million Series B funding round to finalize its preclinical work and fund the ...

"The claim that the FDA is suspending routine food safety inspections is false. FDA is actively working to ensure continuity of operations during the reorganization period and remains committed to ...

News that 2,000 unsold and spanking new condos sit empty in Vancouver – where everyone says there’s a ‘housing crisis’ – made ...

The Global Intravenous Catheters Market is on a steady growth trajectory, driven by rising healthcare demands, an aging population, and continuous innovation in intravenous (IV) therapy technologies.

Nearly half of sequencing data labeled as endometriosis lacks true disease representation, highlighting the urgent need for more diverse and accurate tissue sampling to advance research in this ...

Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value ...

OXURION - Oxurion announces the signing of a binding agreement to acquire French biometrics specialist Axiodis CRO ...

Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bw158 ...

Shares of NeurAxis, Inc. NRXS have gained 13.3% since the company reported its earnings for the quarter ended March 31, 2025. This compares to the S&P 500 Index’s 4.3% growth over the same time frame.